相关实验视频

Updated: May 26, 2025

Intrarenal Injection of Escherichia coli in a Rat Model of Pyelonephritis

Intrarenal Injection of Escherichia coli in a Rat Model of Pyelonephritis

Published on: July 18, 2017

复合库申注射可以通过大麻素受体1改善大鼠的辐射肠炎

Wenjing Xu^1,2, Liping Gao², Wenjuan Zou²

¹Precision Medicine Center, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, 400010, China.

BMC complementary medicine and therapies

|February 22, 2025

概括

复合库申注射 (CKI) 针对大麻素受体1治疗辐射肠炎. 这项研究阐明了CCI的机制,减少炎症和氧化应激,改善了阴茎组织的健康.

科学领域:

药理学和胃肠病学药理学和胃肠病学
分子生物学和信号通路

背景情况:

辐射肠炎是腹部放射治疗的衰弱副作用.
复合库申注射 (CKI) 在缓解辐射肠炎症状方面显示出临床前景.
在CKI治疗效果的基础上,精确的分子机制在很大程度上仍未被探索.

研究的目的:

阐明复合库申注射 (CKI) 在治疗辐射肠炎中的潜在分子标和机制.
调查大麻素受体1 (CB1) 在CKI抗炎和保护作用中的作用.

主要方法:

网络药理学被用来预测CKI对辐射肠炎的目标.
进行了基因本体学 (GO) 和基因和基因组的京都百科全书 (KEGG) 途径分析.
建立了一种辐射肠炎的老鼠模型,并用CKI,CB1激动剂或CB1抗剂治疗,以评估治疗疗效和分子变化.

主要成果:

网络药理学确定了大麻素受体1 (CB1) 作为CKI的潜在目标.
CKI治疗显著改善了阴茎损伤,减少了炎症细胞透,并降低了促炎细胞因子 (MCP1,TNF-α,IL-1β).
CKI增强了抗氧化酶活动 (SOD,GSH-Px),降低了氧化应激标志物 (MDA,ROS,NO),抑制了NF-κB信号传递,并降低了NOX4和p-p38 MAPK表达.

结论:

复合库申注射 (CKI) 对辐射肠炎有治疗作用.
CKI的机制涉及向大麻素受体1 (CB1) 途径.
CKI显示出抗炎和抗氧化特性,为辐射肠炎提供了潜在的治疗策略.

关键词:

大麻素受体1 1 大麻素受体复合的库申注射复合的库申注射炎症途径的炎症途径网络药理学网络药理学氧化应激是一种氧化应激.辐射肠炎是一种辐射肠炎.

更多相关视频

Cecal Ligation Puncture Procedure

Cecal Ligation Puncture Procedure

Published on: May 7, 2011

Operant Protocols for Assessing the Cost-benefit Analysis During Reinforced Decision Making by Rodents

Operant Protocols for Assessing the Cost-benefit Analysis During Reinforced Decision Making by Rodents

Published on: September 10, 2018

相关概念视频

Chemotherapy-Induced Nausea and Vomiting: Cannabinoids

Chemotherapy-Induced Nausea and Vomiting: Cannabinoids

Tetrahydrocannabinol (THC) is a phytocannabinoid that primarily interacts with the CB1 receptor, a type of G protein-coupled receptor (GPCR) predominantly in and around the chemoreceptor trigger zone (CTZ) and emetic center. THC also blocks the serotonin receptor activity in the dorsal vagal complex (DVC) by inhibiting serotonin release. THC exerts its anti-emetic effects through these interactions, which are beneficial for patients undergoing chemotherapy.
Two synthetic agonists of THC,...

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...